Search
Eptifibatide (Integrilin)
Tradename: Integrilin.
Indications:
1) adjunctive agent with angioplasty (PTCA, PCI)
- indicated for patients who have undergone PCI
2) may be useful for acute coronary syndrome
- without persistent ST segment elevation [2]
- only in conjunction with PTCA [5] Conraindications:
- renal failure, serum creatinine > 4.0 mg/dL [4]
- not recommended for patients with unstable angina or NSTEMI who have received dual antiplatelet therapy & are symptom free [4]
- administration prior to PCI
Dosage: 0/5 ug/kg/min for 12 hours
Injection: 0.75 mg/mL
Mechanism of action:
- inhibits glycoprotein IIb/IIIa receptor
Interactions
drug interactions
drug adverse effects (more general classes)
Related
glycoprotein IIB/IIIA
percutaneous transluminal coronary angioplasty (PTCA)
General
glycoprotein IIb/IIIa inhibitor
Database Correlations
PUBCHEM correlations
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 2000
- Journal Watch 22(6):47, 2002
Boersma E, Harrington RA, Moliterno DJ et al
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary
syndromes: a meta-analysis of all major randomised clinical trials.
Lancet. 2002 Jan 19;359(9302):189-98
PMID: 11812552
- Giugliano RP, White JA, Bode C et al
Early versus delayed, provisional eptifibatide in acute
coronary syndromes.
N Engl J Med. 2009 May 21;360(21):2176-90.
PMID: 19332455
- NEJM Knowledge+ Question of the Week. Nov 19, 2019
https://knowledgeplus.nejm.org/question-of-week/53/
- Medical Knowledge Self Assessment Program (MKSAP) 16, 19
American College of Physicians, Philadelphia 2012, 2022